Podcasts about doebele

  • 8PODCASTS
  • 29EPISODES
  • 11mAVG DURATION
  • ?INFREQUENT EPISODES
  • Mar 15, 2022LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about doebele

Latest podcast episodes about doebele

Lung Cancer Considered
Breakthrough Therapies NTRK With Robert Doebele

Lung Cancer Considered

Play Episode Listen Later Mar 15, 2022 32:59


In this episode of Lung Cancer Considered, host Dr. Narjust Duma talks with Dr. Robert C. Doebele, Co-Founder and Chief Scientific Officer, Rain Therapeutics about NTKR gene fusions, including recent and emerging breakthrough therapies.

Smart Athlete Podcast
Ep. 84 - Dr. Robert Doebele - Targeted Therapy

Smart Athlete Podcast

Play Episode Listen Later Jan 1, 2021 54:04


I speak today to a former collegiate swimmer and co-founder of Rain Therapeutics, Dr. Robert Doebele. As the saying goes, "when one door closes, another door opens". This is how the story of Dr. Robert went for his collegiate swimming career. Which ends up with him winding his way around to the path that he's on today. After a time in academia he's left for more full-time work in private practice at Rain Therapeutics. Though I often think of the transition from one job to another as being jarring - Dr. Robert's story shows me how things can go much more smoothly with some planning ahead of time. Dr. Robert specializes in researching cures for very specific kinds of lung cancer. These solutions are often referred to as targeted therapies. We talk about the differences between the broad strokes of chemo and he explains to me how this "targeted therapy" works. If you need a little hope for the future then listen to my conversation with Dr. Robert Doebele and know that there are great people working on creating a brighter future for humanity.

The Holden Village Podcast
Theological Symbolism in the Music of J.S. Bach

The Holden Village Podcast

Play Episode Listen Later Jan 1, 2020 9:21


"Bach is certainly one of the greatest Lutheran composers ever. However, there are many who think he was not just musician and composer, but equal parts theologian. The main ways he embedded theology into music were through word painting and cross and number symbolism. Bach always signed his manuscripts, SDG "Soli Deo Gloria" to God alone be the glory. The embedded symbolism was intended for God." Dr. Alexa Doebele is associate professor of music and Director of Choral Activities at Concordia University Wisconsin, where she conducts three choirs in addition to teaching undergraduate and graduate courses in music education, conducting, and choral literature. She is a frequent clinician, adjudicator, and guest conductor, and is active as an editor of choral music. Prior to her arrival in Wisconsin, Dr. Doebele served as the Director of Music at Holy Cross Lutheran Church in Wheat Ridge, Colorado. Her research interests intersect with her faith life through her study of the choral music of J. S. Bach and William Byrd. She is also active as both a solo and choral singer, most recently with Vox Antiqua, an early music ensemble for which she was also the artistic director, and previously with the Milwaukee Choral Artists, the Colorado Conductors' Chorus, and the Ars Nova Singers. She completed a bachelor's degree (double major in vocal performance and German language and literature) at Washington University in St. Louis and her Master of Music Education and Doctor of Musical Arts degrees at the University of Colorado. To learn more about Holden Village, visit: www.holdenvillage.org or to listen to more audio recordings visit: http://audio.holdenvillage.org The Holden Village Podcast is accessible through Apple iTunes, Google Play Music, Spotify, TuneIn, iHeart Radio, and most podcast apps. To contact the podcast author, podcast@holdenvillage.org

onward. upward.  // Lamb School // Purdue University //
Connie Doebele, Managing Director, C-SPAN Center at Purdue

onward. upward. // Lamb School // Purdue University //

Play Episode Listen Later Mar 27, 2019 39:02


In this episode, Connie Doebele, C-SPAN Center Managing Director, talks about C-SPAN, the C-SPAN Center, the C-SPAN Archives, Brian Lamb and more. 

GRACEcast Lung Cancer Video
Questions & Answers with Drs. Doebele and Shaw; Moderated by Craig Uthe

GRACEcast Lung Cancer Video

Play Episode Listen Later Oct 26, 2014 13:50


Acquired Resistance Forum Video #10: Online advocate and ROS1 patient "Craig In PA" Uthe leads a Q&A with speakers from videos #8 and #9 at the Acquired Resistance in Lung Cancer Patient Forum.

university online colorado brain cancer hospitals patients massachusetts resistance trials forum shaw new york mets clinical lung acquired moderated alk metastases ros1 uthe gracecast cancergrace acquired resistance crizotinib alimta pemetrexed doebele xalkori acquired resistance forum video lung cancer patient forum craig in pa uthe
GRACEcast ALL Subjects audio and video
Questions & Answers with Drs. Doebele and Shaw; Moderated by Craig Uthe

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Oct 26, 2014 13:50


Acquired Resistance Forum Video #10: Online advocate and ROS1 patient "Craig In PA" Uthe leads a Q&A with speakers from videos #8 and #9 at the Acquired Resistance in Lung Cancer Patient Forum.

university online colorado brain cancer hospitals patients massachusetts resistance trials forum shaw new york mets clinical lung acquired moderated alk metastases ros1 uthe gracecast cancergrace acquired resistance crizotinib alimta pemetrexed doebele xalkori acquired resistance forum video lung cancer patient forum craig in pa uthe
GRACEcast
Questions & Answers with Drs. Doebele and Shaw; Moderated by Craig Uthe

GRACEcast

Play Episode Listen Later Oct 26, 2014 13:50


Acquired Resistance Forum Video #10: Online advocate and ROS1 patient "Craig In PA" Uthe leads a Q&A with speakers from videos #8 and #9 at the Acquired Resistance in Lung Cancer Patient Forum.

university online colorado brain cancer hospitals patients massachusetts resistance trials forum shaw new york mets clinical lung acquired moderated alk metastases ros1 uthe gracecast cancergrace acquired resistance crizotinib alimta pemetrexed doebele xalkori acquired resistance forum video lung cancer patient forum craig in pa uthe
GRACEcast
Mechanisms of ALK Resistance & Implications for Treatment

GRACEcast

Play Episode Listen Later Oct 21, 2014 22:46


Acquired Resistance Forum Video #8: Dr. Robert Doebele of the University of Colorado Cancer Center spoke to ALK and ROS1 patients about how and why their cancers become resistant to treatment and what options are available.

university colorado brain cancer patients treatments resistance trials forum implications new york mets clinical lung acquired mechanisms alk metastases ros1 gracecast cancergrace colorado cancer center crizotinib alectinib alimta pemetrexed doebele ceritinib xalkori zykadia acquired resistance forum video
GRACEcast Lung Cancer Video
Mechanisms of ALK Resistance & Implications for Treatment

GRACEcast Lung Cancer Video

Play Episode Listen Later Oct 21, 2014 22:46


Acquired Resistance Forum Video #8: Dr. Robert Doebele of the University of Colorado Cancer Center spoke to ALK and ROS1 patients about how and why their cancers become resistant to treatment and what options are available.

university colorado brain cancer patients treatments resistance trials forum implications new york mets clinical lung acquired mechanisms alk metastases ros1 gracecast cancergrace colorado cancer center crizotinib alectinib alimta pemetrexed doebele ceritinib xalkori zykadia acquired resistance forum video
GRACEcast ALL Subjects audio and video
Mechanisms of ALK Resistance & Implications for Treatment

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Oct 21, 2014 22:46


Acquired Resistance Forum Video #8: Dr. Robert Doebele of the University of Colorado Cancer Center spoke to ALK and ROS1 patients about how and why their cancers become resistant to treatment and what options are available.

university colorado brain cancer patients treatments resistance trials forum implications new york mets clinical lung acquired mechanisms alk metastases ros1 gracecast cancergrace colorado cancer center crizotinib alectinib alimta pemetrexed doebele ceritinib xalkori zykadia acquired resistance forum video
GRACEcast
Understanding Acquired Resistance in ALK+ Lung Cancer

GRACEcast

Play Episode Listen Later Sep 30, 2014 2:52


Dr. Robert Doebele explains why he feels that repeat biopsies help researchers better understand why ALK+ lung cancer patients become resistant to current treatments - and why some do better than expected. February 2014

university colorado cancer resistance repeat progression lung acquired lung cancer biopsies alk nsclc gracecast cancergrace crizotinib acquired resistance alectinib ceritinib doebele xalkori rebiopsy zykadia
GRACEcast Lung Cancer Video
Understanding Acquired Resistance in ALK+ Lung Cancer

GRACEcast Lung Cancer Video

Play Episode Listen Later Sep 30, 2014 2:52


Dr. Robert Doebele explains why he feels that repeat biopsies help researchers better understand why ALK+ lung cancer patients become resistant to current treatments - and why some do better than expected. February 2014

university colorado cancer resistance repeat progression lung acquired lung cancer biopsies alk nsclc gracecast cancergrace crizotinib acquired resistance alectinib ceritinib doebele xalkori rebiopsy zykadia
GRACEcast ALL Subjects audio and video
Understanding Acquired Resistance in ALK+ Lung Cancer

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Sep 30, 2014 2:52


Dr. Robert Doebele explains why he feels that repeat biopsies help researchers better understand why ALK+ lung cancer patients become resistant to current treatments - and why some do better than expected. February 2014

university colorado cancer resistance repeat progression lung acquired lung cancer biopsies alk nsclc gracecast cancergrace crizotinib acquired resistance alectinib ceritinib doebele xalkori rebiopsy zykadia
GRACEcast
Treating Brain Mets in ALK+ Lung Cancer

GRACEcast

Play Episode Listen Later Sep 28, 2014 4:30


For ALK+ lung cancer patients, brain metastases are a common concern. Dr. Robert Doebele discusses the options available to treat brain mets as well as drugs that may break through the blood/brain barrier. February 2014

GRACEcast Lung Cancer Video
Treating Brain Mets in ALK+ Lung Cancer

GRACEcast Lung Cancer Video

Play Episode Listen Later Sep 28, 2014 4:30


For ALK+ lung cancer patients, brain metastases are a common concern. Dr. Robert Doebele discusses the options available to treat brain mets as well as drugs that may break through the blood/brain barrier. February 2014

GRACEcast ALL Subjects audio and video
Treating Brain Mets in ALK+ Lung Cancer

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Sep 28, 2014 4:30


For ALK+ lung cancer patients, brain metastases are a common concern. Dr. Robert Doebele discusses the options available to treat brain mets as well as drugs that may break through the blood/brain barrier. February 2014

Lung Cancer Update
LCU1 2014 | Robert C Doebele, MD, PhD

Lung Cancer Update

Play Episode Listen Later Jun 10, 2014 30:38


Conversations with Oncology Investigators. Bridging the Gap between Research and Patient Care. Interview with Robert C Doebele, MD, PhD conducted by Neil Love, MD. Produced by Research To Practice.

GRACEcast ALL Subjects audio and video
Dr. Bob Doebele: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Aug 6, 2013 2:48


Dr. Bob Doebele from the University of Colorado, offers his insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent.

GRACEcast Lung Cancer Video
Dr. Bob Doebele: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?

GRACEcast Lung Cancer Video

Play Episode Listen Later Aug 6, 2013 2:48


Dr. Bob Doebele from the University of Colorado, offers his insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent.

GRACEcast
Dr. Bob Doebele: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?

GRACEcast

Play Episode Listen Later Aug 6, 2013 2:48


Dr. Bob Doebele from the University of Colorado, offers his insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent.

GRACEcast ALL Subjects audio and video
Dr. Bob Doebele on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Jul 11, 2013 2:06


Dr. Bob Doebele from the University of Colorado, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.

GRACEcast Lung Cancer Video
Dr. Bob Doebele on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment

GRACEcast Lung Cancer Video

Play Episode Listen Later Jul 11, 2013 2:06


Dr. Bob Doebele from the University of Colorado, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.

GRACEcast
Dr. Bob Doebele on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment

GRACEcast

Play Episode Listen Later Jul 11, 2013 2:06


Dr. Bob Doebele from the University of Colorado, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.

GRACEcast ALL Subjects audio and video
What Molecular Markers Do You Prioritize for Molecular Testing in Advanced NSCLC, and Who do you Test?

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Mar 10, 2013 1:45


Dr. Bob Doebele from the University of Colorado reviews which molecular markers have the strongest evidence to support routine testing, and which patients with advanced non-small cell lung cancer he favors molecular testing for. 

GRACEcast Lung Cancer Video
What Molecular Markers Do You Prioritize for Molecular Testing in Advanced NSCLC, and Who do you Test?

GRACEcast Lung Cancer Video

Play Episode Listen Later Mar 10, 2013 1:45


Dr. Bob Doebele from the University of Colorado reviews which molecular markers have the strongest evidence to support routine testing, and which patients with advanced non-small cell lung cancer he favors molecular testing for. 

GRACEcast
What Molecular Markers Do You Prioritize for Molecular Testing in Advanced NSCLC, and Who do you Test?

GRACEcast

Play Episode Listen Later Mar 10, 2013 1:45


Dr. Bob Doebele from the University of Colorado reviews which molecular markers have the strongest evidence to support routine testing, and which patients with advanced non-small cell lung cancer he favors molecular testing for. 

GRACEcast ALL Subjects audio and video
Dr. Bob Doebele: Will We Be Able to Use Molecular Markers and Apply Targeted Therapies to Broader Lung Cancer Subtypes in the Near Future?

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Feb 27, 2013 1:46


Dr. Bob Doebele from the University of Colorado offers his perspective on whether targeted therapies will be able to applied to broader populations of patients with advanced NSCLC than those primarily with minimal smoking histories and an adenocarcinoma.

GRACEcast Lung Cancer Video
Dr. Bob Doebele: Will We Be Able to Use Molecular Markers and Apply Targeted Therapies to Broader Lung Cancer Subtypes in the Near Future?

GRACEcast Lung Cancer Video

Play Episode Listen Later Feb 27, 2013 1:46


Dr. Bob Doebele from the University of Colorado offers his perspective on whether targeted therapies will be able to applied to broader populations of patients with advanced NSCLC than those primarily with minimal smoking histories and an adenocarcinoma.

GRACEcast
Dr. Bob Doebele: Will We Be Able to Use Molecular Markers and Apply Targeted Therapies to Broader Lung Cancer Subtypes in the Near Future?

GRACEcast

Play Episode Listen Later Feb 27, 2013 1:46


Dr. Bob Doebele from the University of Colorado offers his perspective on whether targeted therapies will be able to applied to broader populations of patients with advanced NSCLC than those primarily with minimal smoking histories and an adenocarcinoma.